Changing the Paradigm to Understand and Manage Atrial Fibrillation

  • Gheorghe-Andrei DanEmail author
Part of the Current Cardiovascular Therapy book series (CCT)


Atrial Fibrillation (AF) is a very prevalent disease with increasing incidence with important consequences on outcome and quality of life. Despite improvement in our knowledge about the mechanisms involved in the initiation and perpetuation of AF the therapy is still challenging. The current statement of the clinical equivalence between rate control and rhythm control strategy is biased by the efficacy and safety limitations of the current antiarrhythmic drugs and by treating AF as an exclusively homogenous electrical disease. A better understanding of the complex mechanisms for AF initiation and perpetuation helps to change the management paradigm and to understand better the targets of the future therapy aimed to restore and maintain the sinus rhythm with the expected long-term consequences on outcome.


Atrial Fibrillation Action Potential Duration Persistent Atrial Fibrillation Electrical Remodel Maintain Sinus Rhythm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Antiarrhythmic drug therapy


Atrial fibrillation


Action potential duration


Congestive heart failure


Ejection fraction


Heart rate




Quality of life


Randomized controlled trials


Sinus rhythm


Tumor Growth Factor β1


Transient ischemic attack




  1. 1.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–5.PubMedCrossRefGoogle Scholar
  2. 2.
    De S, Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.CrossRefGoogle Scholar
  3. 3.
    Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Bauersachs R, Breithardt G. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004;110(9):1042–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. New Engl J Med. 2002;347(23):1825–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M, Guerra PG, Hohnloser SH, Lee KL, Macle L, Nattel S, Pedersen OD, Stevenson LW, Thibault B, Waldo AL, Wyse DG, Roy D. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;55(17):1796–802.PubMedCrossRefGoogle Scholar
  8. 8.
    de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165(3):258–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Al-khatib SM, Lapointe NA, Chatterjee R. Treatment of atrial fibrillation. Eff Health Care Program. 2013; Comparativ(119).Google Scholar
  10. 10.
    Vora A, Karnad D, Goyal V, Naik A, Gupta A, Lokhandwala Y, Kulkarni H, Singh BN. Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. J Cardiovas Pharmacol Ther. 2004;9(2):65–73.CrossRefGoogle Scholar
  11. 11.
    Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest. 2004;126(2):476–86.PubMedCrossRefGoogle Scholar
  12. 12.
    Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Brignole M, Menozzi C, Gasparini M, Bongiorni MG, Botto GL, Ometto R, Alboni P, Bruna C, Vincenti A, Verlato R. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J. 2002;23(11):892–900.PubMedCrossRefGoogle Scholar
  14. 14.
    Petrac D, Radić B, Radeljić V, Hamel D, Filipović J. Ventricular pacing vs dual chamber pacing in patients with persistent atrial fibrillation after atrioventricular node ablation: open randomized study. Croat Med J. 2005;46(6):922–8.PubMedGoogle Scholar
  15. 15.
    Martin-Doyle W, Essebag V, Zimetbaum P, Reynolds MR. Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials. J Cardiovasc Electrophysiol. 2011;22(5):548–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JMO, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey J-Y, O’Hara G, Pedersen OD, Rouleau J-L, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. New Engl J Med. 2008;358(25):2667–77.PubMedCrossRefGoogle Scholar
  17. 17.
    Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, Essebag V, Eisenberg MJ, Wynant W, Richard H, Pilote L. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Int Med. 2012;172(13):997–1004.CrossRefGoogle Scholar
  18. 18.
    Zimetbaum P. Is rate control or rhythm control preferable in patients with atrial fibrillation? An argument for maintenance of sinus rhythm in patients with atrial fibrillation. Circulation. 2005;111(23):3150–6. discussion 3156–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH. Subclinical atrial fibrillation and the risk of stroke. New Engl J Med. 2012;366(2):120–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109(12):1509–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey J-Y, Merioua I, Pedrazzini L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub W. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol. 2011;58(5):493–501.PubMedCrossRefGoogle Scholar
  22. 22.
    De Vos CB, Breithardt G, Camm AJ, Dorian P, Kowey PR, Le Heuzey J-Y, Naditch-Brûlé L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub WS, Crijns HJ. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of atrial fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J. 2012;163(5):887–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Le Heuzey J-Y, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy J-M. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597–605.PubMedCrossRefGoogle Scholar
  24. 24.
    Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. New Engl J Med. 2000;342(13):913–20.PubMedCrossRefGoogle Scholar
  26. 26.
    The ‘Sicilian Gambit’. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The task force of the working group on arrhythmias of the European Society of Cardiology. Eur Heart J. 1991;12(10):1112–31.Google Scholar
  27. 27.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. New Engl J Med. 1991;324(12):781–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993;270(20):2451–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Lafuente-Lafuente C, Longas-Tejero MA, Bergmann J-F, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049.PubMedGoogle Scholar
  30. 30.
    Burch D. Do not harm. New Sci. 2010;Juin 12, no. Opinion 969.Google Scholar
  31. 31.
    Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Kristensen SD, Le Heuzey J-Y, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FWA. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Eur Heart J. 2012;33(21):2719–47.PubMedCrossRefGoogle Scholar
  32. 32.
    Kirchhof P, Lip GYH, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options–a report from the 3rd atrial fibrillation competence NETwork/European heart rhythm association consensus conference. Europace. 2012;14(1):8–27.PubMedCrossRefGoogle Scholar
  33. 33.
    Wyse DG, Gersh BJ. Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation. 2004;109(25):3089–95.PubMedCrossRefGoogle Scholar
  34. 34.
    Cosio FG, Aliot E, Botto GL, Heidbüchel H, Geller CJ, Kirchhof P, De Haro J-C, Frank R, Villacastin JP, Vijgen J, Crijns H. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace. 2008;10(1):21–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian registry of atrial fibrillation. Am Heart J. 2005;149(3):489–96.PubMedCrossRefGoogle Scholar
  36. 36.
    Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen W-K, Gersh BJ. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation. 2007;115(24):3050–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Saksena S, Hettrick DA, Koehler JL, Grammatico A, Padeletti L. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am Heart J. 2007;154(5):884–92.PubMedCrossRefGoogle Scholar
  38. 38.
    de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen R-JS, van den Heijkant AC, Allessie MA, Crijns HJGM. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725–31.PubMedCrossRefGoogle Scholar
  39. 39.
    Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA. 1994;271(11):840–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373(9665):739–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107(1):85–91.PubMedCrossRefGoogle Scholar
  43. 43.
    Everett BM, Cook NR, Conen D, Chasman DI, Ridker PM, Albert CM. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J. 2013;34(29):2243–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Lubitz SA, Husser D. Genomic risk scores in atrial fibrillation: predicting the unpredictable? Eur Heart J. 2013;34(29):2227–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Darbar D. Genetics of atrial fibrillation: rare mutations, common polymorphisms, and clinical relevance. Heart Rhythm. 2008;5(3):483–6. the official journal of the Heart Rhythm Society.PubMedCrossRefGoogle Scholar
  46. 46.
    Darbar D, Roden DM. Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat Rev Cardiol. 2013;10(6):317–29.PubMedCrossRefGoogle Scholar
  47. 47.
    Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Müller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dörr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, Borkovich M, Harris TB, Lin H, Völker U, Völzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann H-E, Witteman JCM, Kao WHL, Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, McKnight B, Sjögren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka T, Stricker BHC, Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, Kääb S. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44(6):670–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Nia AM, Caglayan E, Gassanov N, Zimmermann T, Aslan O, Hellmich M, Duru F, Erdmann E, Rosenkranz S, Er F. Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. PloS One. 2010;5(7):e11421.PubMedCrossRefGoogle Scholar
  49. 49.
    Darbar D, Motsinger AA, Ritchie MD, Gainer JV, Roden DM. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm. 2007;4(6):743–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, Villalon ML, Vasan RS, Pencina MJ, Levy D, Larson MG, Ellinor PT, Benjamin EJ. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010;304(20):2263–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. New Engl J Med. 1998;339(10):659–66.PubMedCrossRefGoogle Scholar
  52. 52.
    Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62–73.PubMedCrossRefGoogle Scholar
  53. 53.
    Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol. 2013;9(1):71–88.PubMedCrossRefGoogle Scholar
  54. 54.
    Workman AJ, Pau D, Redpath CJ, Marshall GE, Russell JA, Norrie J, Kane KA, Rankin AC. Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm. 2009;6(4):445–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, Nattel S, Wehrens XHT, Dobrev D. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059–70.PubMedCrossRefGoogle Scholar
  56. 56.
    Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, Neumann K, Seipelt R, Schöndube FA, Hasenfuss G, Maier LS. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106(6):1134–44.PubMedCrossRefGoogle Scholar
  57. 57.
    Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J Cardiovasc Electrophysiol. 2012;23(7):797–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res. 2007;101(8):755–8.PubMedGoogle Scholar
  60. 60.
    Morita N, Sovari AA, Xie Y, Fishbein MC, Mandel WJ, Garfinkel A, Lin S-F, Chen P-S, Xie L-H, Chen F, Qu Z, Weiss JN, Karagueuzian HS. Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am J Physiol Heart Circ Physiol. 2009;297(5):H1594–605.PubMedCrossRefGoogle Scholar
  61. 61.
    Kamkin A, Kiseleva I, Lozinsky I, Scholz H. Electrical interaction of mechanosensitive fibroblasts and myocytes in the heart. Basic Res Cardiol. 2005;100(4):337–45.PubMedCrossRefGoogle Scholar
  62. 62.
    Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;Facm I.Google Scholar
  63. 63.
    MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res. 2000;46(2):257–63.PubMedCrossRefGoogle Scholar
  64. 64.
    Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhwar N, Lee RJ, Tseng ZH, Lee BK, Olgin JE. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010;7(2):149–54.PubMedCrossRefGoogle Scholar
  65. 65.
    Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, Tseng ZH, Badhwar N, Lee BK, Lee RJ, Scheinman MM, Olgin JE. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008;5(2):215–21. the official journal of the Heart Rhythm Society.PubMedCrossRefGoogle Scholar
  66. 66.
    Camm AJ, Camm CF, Savelieva I. Medical treatment of atrial fibrillation. J Cardiovasc Med (Hagerstown, Md). 2012;13(2):97–107.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.University of Medicine “Carol Davila”BucharestRomania
  2. 2.Internal Medicine Clinic, Cardiology DepartmentColentina University HospitalBucharestRomania

Personalised recommendations